Cargando…

A Phase 3 Study to Compare Delafloxacin With Moxifloxacin for the Treatment of Adults With Community-Acquired Bacterial Pneumonia (DEFINE-CABP)

BACKGROUND: The clinical and economic burden of community-acquired bacterial pneumonia (CABP) is significant and is anticipated to increase as the population ages and pathogens become more resistant. Delafloxacin is a fluoroquinolone antibiotic approved in the United States for the treatment of adul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Horcajada, Juan P, Salata, Robert A, Álvarez-Sala, Rodolfo, Nitu, Floarea Mimi, Lawrence, Laura, Quintas, Megan, Cheng, Chun-Yen, Cammarata, Sue
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6975251/ https://www.ncbi.nlm.nih.gov/pubmed/31988972 http://dx.doi.org/10.1093/ofid/ofz514

Ejemplares similares

2232. A Global Phase 3 Study of Delafloxacin (DLX) Compared with Moxifloxacin (MOX) in Patients with Community-acquired Bacterial Pneumonia (CABP)
por: Salata, Robert, et al.
Publicado: (2019)

Efficacy of Delafloxacin versus Moxifloxacin against Bacterial Respiratory Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Microbiology Results from the Delafloxacin Phase 3 CABP Trial
por: McCurdy, Sandra, et al.
Publicado: (2020)

2228. Treatment of Community-Acquired Bacterial Pneumonia (CABP) in Patients with Diabetes: Outcomes from a Global Phase 3 Study of Delafloxacin (DLX)
por: Kaidashev, Igor, et al.
Publicado: (2019)

2234. Outcomes by Age and Gender from a Global Phase 3 Study of Delafloxacin (DLX) in Community-Acquired Bacterial Pneumonia (CABP)
por: Madej, Andrzej, et al.
Publicado: (2019)

2230. Analysis of the Microbiological Data from the Delafloxacin (DLX) Phase 3 Community-acquired Bacterial Pneumonia (CABP) Trial
por: McCurdy, Sandra, et al.
Publicado: (2019)

Safety of Delafloxacin: Focus on Adverse Events of Special Interest
por: Lodise, Thomas, et al.
Publicado: (2018)

Delafloxacin Pharmacokinetics in Subjects With Varying Degrees of Renal Function
por: Hoover, Randall K., et al.
Publicado: (2017)

Clinical Pharmacology of Delafloxacin in Patients With Hepatic Impairment
por: Hoover, Randall, et al.
Publicado: (2016)

2378. Resolution of Signs and Symptoms (S&S) of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) With Delafloxacin (DLX) IV/Oral Therapy
por: Pullman, John, et al.
Publicado: (2018)

470. Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in Patients with Significant Drug Abuse: Outcomes from Global Phase 3 Studies of Delafloxacin (DLX)
por: Overcash, J Scott, et al.
Publicado: (2019)

Efficacy of Omadacycline Versus Moxifloxacin in the Treatment of Community-Acquired Bacterial Pneumonia by Disease Severity: Results From the OPTIC Study
por: Ramirez, Julio, et al.
Publicado: (2021)

Human Target Attainment Probabilities for Delafloxacin against Escherichia coli and Pseudomonas aeruginosa
por: Hoover, Randall, et al.
Publicado: (2017)

A Comparison of the Efficacy and Safety of Intravenous Followed by Oral Delafloxacin With Vancomycin Plus Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Multinational, Double-Blind, Randomized Study
por: O’Riordan, William, et al.
Publicado: (2018)

Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study
por: Pullman, J, et al.
Publicado: (2017)

In Vitro Activity of Delafloxacin and Microbiological Response against Fluoroquinolone-Susceptible and Nonsusceptible Staphylococcus aureus Isolates from Two Phase 3 Studies of Acute Bacterial Skin and Skin Structure Infections
por: McCurdy, S., et al.
Publicado: (2017)

Analysis of Pooled Phase III Efficacy Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections
por: Giordano, Philip A, et al.
Publicado: (2019)

Serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae isolates from a Phase III community-acquired bacterial pneumonia (CABP) trial
por: McCurdy, S P, et al.
Publicado: (2021)

Model-Based Efficacy and Toxicity Comparisons of Moxifloxacin for Multidrug-Resistant Tuberculosis
por: Yun, Hwi-Yeol, et al.
Publicado: (2021)

Increased Moxifloxacin Dosing Among Patients With Multidrug-Resistant Tuberculosis With Low-Level Resistance to Moxifloxacin Did Not Improve Treatment Outcomes in a Tertiary Care Center in Mumbai, India
por: Tornheim, Jeffrey A, et al.
Publicado: (2021)

Comparison of the in vitro antibacterial activity of ofloxacin, levofloxacin, moxifloxacin, sitafloxacin, finafloxacin, and delafloxacin against Mycobacterium tuberculosis strains isolated in China
por: Kong, Yaoyao, et al.
Publicado: (2023)

684. Cardiac Safety in Adults with Community-Acquired Bacterial Pneumonia (CABP) Treated with Lefamulin (LEF) or Moxifloxacin (MOX): Analysis of Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Study Results
por: Darpo, Borje, et al.
Publicado: (2019)

699. Hepatobiliary Safety in Adults With Community-Acquired Bacterial Pneumonia (CABP) Treated With Lefamulin (LEF) or Moxifloxacin (MOX): Pooled Analysis of Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Study Results
por: Lewis, James H, et al.
Publicado: (2019)

2377. Outcomes in Patients With History of Cardiac or Vascular Disease (CV) During Treatment of Acute Bacterial Skin And Skin Structure Infection (ABSSSI) With Delafloxacin (DLX) vs. Vancomycin/Aztreonam (VAN/AZ)
por: Oguchi, Godson, et al.
Publicado: (2018)

gyrA Mutations in Mycoplasma genitalium and Their Contribution to Moxifloxacin Failure: Time for the Next Generation of Resistance-Guided Therapy
por: Murray, Gerald L, et al.
Publicado: (2023)

Lack of CaBP1/Caldendrin or CaBP2 Leads to Altered Ganglion Cell Responses
por: Sinha, Raunak, et al.
Publicado: (2016)

2386. Efficacy of Lefamulin (LEF) vs. Moxifloxacin (MOX) Against Common Pathogens in Adults With Community-Acquired Bacterial Pneumonia (CABP): Results From the Phase 3 Lefamulin Evaluation Against Pneumonia (LEAP 1) Study
por: File, Thomas, et al.
Publicado: (2018)

Membrane targeting of the EF-hand containing calcium-sensing proteins CaBP7 and CaBP8
por: McCue, Hannah V., et al.
Publicado: (2009)

A randomized, double-blind, Phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin
por: Kingsley, Jeff, et al.
Publicado: (2016)

Delafloxacin: First Global Approval
por: Markham, Anthony
Publicado: (2017)

2233. Efficacy and Symptom Resolution by Visit in Adults With Community-Acquired Bacterial Pneumonia (CABP) Treated With Lefamulin (LEF) or Moxifloxacin (MOX): Pooled Analysis of Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Study Results
por: Schranz, Jennifer, et al.
Publicado: (2019)

Health-Related Quality of Life as Measured by the 12-Item Short-Form Survey Among Adults With Community-Acquired Bacterial Pneumonia who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials
por: Lodise, Thomas P, et al.
Publicado: (2020)

Lefamulin vs moxifloxacin for community-acquired bacterial pneumonia
por: Tang, Hung-Jen, et al.
Publicado: (2020)

Determination of the Membrane Topology of the Small EF-Hand Ca(2+)-Sensing Proteins CaBP7 and CaBP8
por: McCue, Hannah V., et al.
Publicado: (2011)

Community-Acquired Bacterial Pneumonia—Changing Epidemiology, Resistance Patterns, and Newer Antibiotics: Spotlight on Delafloxacin
por: Sharma, Roopali, et al.
Publicado: (2020)

Correction to: Delafloxacin: First Global Approval
por: Markham, Anthony
Publicado: (2018)

Association between Risk Factors and the Existence of Lung Malignancies in a Population from the South-West Romania: A Single-Center Study
por: GHEORGHE, ANDREEA-GEORGIANA, et al.
Publicado: (2021)

The Role of Delafloxacin in Patients with Community-Acquired Bacterial Pneumonia in the Outpatient Setting: A Budget Impact Model
por: Lodise, Thomas P., et al.
Publicado: (2020)

Correction to: Community-Acquired Bacterial Pneumonia—Changing Epidemiology, Resistance Patterns, and Newer Antibiotics: Spotlight on Delafloxacin
por: Sharma, Roopali, et al.
Publicado: (2021)

Decalmodulation of Ca(v)1 channels by CaBPs
por: Hardie, Jason, et al.
Publicado: (2015)

The Profile of the Patients with Double Infection HIV and TB in South West of Romania
por: STOICA (CĂLĂRAŞU), CRISTINA, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7p3qgt3gi0mu8vf9a98lk8eibu